Vaccine trials essential to evaluate effectiveness against new COVID-19 variants: GlobalData EP News Bureau Feb 9, 2021 The largest proportion of the ongoing vaccine trials are now in Phase II (38.6 per cent) and Phase III (36.3 per cent), after…
